课题基金 / 基金详情

ANTIBODY

ANTIBODY
抗体
批准号:
7944722
负责人:
Tyler J. Curiel
金额:
$2.74万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-08-03 至 2012-07-31
关键词:
AdjuvantAffinity ChromatographyAnimal Care CommitteesAnimalsAntibodiesAntibody AffinityAntibody FormationAntibody-Producing CellsAntigensBackBacteriaBindingBinding ProteinsBiochemistryBiological AssayBloodCancer CenterCarbohydratesCarrier ProteinsCattleCell ExtractsCell LineCell fusionCellsCellular biologyChargeChimeric ProteinsClone CellsCollaborationsCollectionColumn ChromatographyConditioned Culture MediaConsultationsCoupledCryopreservationCustomDisadvantagedEarEnsureEpitopesEquipmentEventExperimental DesignsFab ImmunoglobulinsFailureFeesFibroblastsFreezingG-substrateGenerationsGrowthHandHarvestHeartHemorrhageHuman ResourcesHybridomasImmune SeraImmune responseImmunoglobulin GImmunoglobulin MImmunoglobulin-Secreting CellsImmunologic MemoryIndividualInjection of therapeutic agentLaboratory PersonnelLaboratory miceLiquid substanceMethodsMissionMolecularMolecular BiologyMolecular MedicineMonoclonal AntibodiesMultiple MyelomaMusNitrogenOryctolagus cuniculusPeptide Nucleic AcidsPeptidesPhosphate BufferPolyethylene GlycolsPopulationPreparationPriceProceduresProcessProductionProteinsPuncture procedureReagentRecombinant Fusion ProteinsRecombinantsRecoveryRelative (related person)ResearchResearch PersonnelResource SharingRestSalineScienceScreening procedureSepharoseSerumSerum-Free Culture MediaServicesSiteSkinSolutionsSourceSpecificitySpleenSplenocyteStagingStudentsTechnologyTestingTherapeutic StudiesTimeTissuesTiterMaxTrainingTumor Cell LineVariantVeinsVial deviceWestern Blottingantigen bindingbasecancer therapycase-basedcostdensitydesignfetalfetal bovine serumhybridoma productioninterestlecturesmeetingsmembermonoclonal antibody productionneoplastic cellnovelpolyclonal antibodyprotein complexprotein functionprotein purificationresearch studyresponse

项目摘要

项目成果

Tyler J. Curiel的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The primary purpose of this shared resource is to generate novel polyclonal and monoclonal antibody reagents, to assist investigators in characterization and optimization of these reagents, and to provide other technical assistance for antibody-related research. Availability of high quality antibody reagents is critical for understanding protein function in normal and neoplastic cells and tissues. We aim to provide antibodies to cancer center members in a timely manner at a reduced cost, relative to commercial custom antibody services. We can also provide an expanded range of services that are not generally available from commercial sources, so that more investigators without expertise or equipment for molecular cell biology or biochemistry can successfully generate and characterize custom antibody reagents. Our most commonly used services include the generation of rabbit polyclonal antibodies, purification and/or testing of polyclonal antibody, generation of mouse polyclonal antibodies, and the generation, purification, characterization and testing of mouse monoclonal antibodies. Other services that we have provided include production and purification of bacterially expressed fusion protein antigens, antibody isotyping, cryopreservation and storage of hybridoma lines, preparation of Fab fragments from existing antibodies, adaptation of hybridoma lines to serum-free culture and recovery of poorly frozen hybridoma cell lines from other sources.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Bladder cancer PD-L1 control of homologous recombination: Basic mechanisms applied to novel treatments
  • 批准号:
    10467877
  • 项目类别:
  • 资助金额:
    $64.67万
  • 财政年份:
    2022
  • 负责人:
    Tyler J. Curiel
  • 依托单位:
Bladder cancer PD-L1 control of homologous recombination: Basic mechanisms applied to novel treatments
  • 批准号:
    10688261
  • 项目类别:
  • 资助金额:
    $62.07万
  • 财政年份:
    2022
  • 负责人:
    Tyler J. Curiel
  • 依托单位:
Regulation of ER-beta Signaling in Carcinogenesis
  • 批准号:
    10092967
  • 项目类别:
  • 资助金额:
    $48.43万
  • 财政年份:
    2019
  • 负责人:
    Tyler J. Curiel
  • 依托单位:
(PQ2) PD-L1/PD-1 signals in aged hosts undergoing cancer immunotherapy
海外基金